iCo Therapeutics Number One in Class in TSX Venture Top 50

iCo Therapeutics Inc. (TSXV:ICO) proudly announced that it has been named the number one company in technology and life science in the TSX Venture 50 for 2013.

As quoted in the press release:

Our positive clinical update on our Phase 2 iDEAL study for the treatment of diabetic macular edema was well received by the sector and investment community, which has been demonstrated in our strong and growing performance in 2012,” said Andrew Rae, President and CEO of iCo Therapeutics. “We expect to announce primary endpoint data from the iDEAL study before the end of the year and have several other catalyst events in 2013.  We aim to continue our 2012 momentum and hope to make the list again next year.

Click here to read the full iCo Therapeutics Inc. (TSXV:ICO) press release.